Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398831 | 0.90 | HCRTR1 (0.57) | HCRTR1HCRTR2LMNATSHRRECQL | |
| SCHEMBL1398834 | 0.90 | HCRTR1 (0.57) | HCRTR1HCRTR2LMNATSHRRECQL | |
| SCHEMBL3058405 | 0.88 | HCRTR1 (0.55) | HCRTR1HCRTR2TSHRRECQLSCN1A | |
| SCHEMBL1398919 | 0.87 | HCRTR1 (0.47) | HCRTR1HCRTR2LMNA | |
| SCHEMBL3058147 | 0.87 | MEN1 (0.48) | HCRTR1HCRTR2LMNAALDH1A1 | |
| SCHEMBL3063124 | 0.85 | TP53 (0.47) | HCRTR1HCRTR2LMNATSHRALDH1A1 | |
| SCHEMBL4299213 | 0.83 | CYP46A1 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL20040364 | 0.82 | HCRTR1 (0.64) | HCRTR1HCRTR2LMNATSHRRECQL | |
| SCHEMBL3318857 | 0.82 | HCRTR1 (0.40) | HCRTR1HCRTR2LMNATSHRRECQL | |
| SCHEMBL3058143 | 0.81 | HCRTR1 (0.49) | HCRTR1HCRTR2LMNATSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885LMNA 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.